Vibegron improves quality‐of‐life measures in patients with overactive bladder: Patient‐reported outcomes from the EMPOWUR study

BACKGROUND: Quality of life (QOL) can be significantly impacted by symptoms of overactive bladder (OAB). Vibegron is a highly selective β(3)‐adrenergic receptor agonist that showed efficacy in treatment of symptoms of OAB in the randomised, double‐blind, placebo‐ and active‐controlled phase 3 EMPOWU...

Descripción completa

Detalles Bibliográficos
Autores principales: Frankel, Jeffrey, Varano, Susann, Staskin, David, Shortino, Denise, Jankowich, Rachael, Mudd, Paul N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244055/
https://www.ncbi.nlm.nih.gov/pubmed/33332699
http://dx.doi.org/10.1111/ijcp.13937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8244055/
https://www.ncbi.nlm.nih.gov/pubmed/33332699
http://dx.doi.org/10.1111/ijcp.13937

Ejemplares similares